New Alzheimer’s research just caught my attention. Scientists at Northwestern found that levetiracetam, a decades-old FDA-approved seizure drug, may stop Alzheimer’s before it starts. Instead of clearing plaques after damage happens, it blocks the production of the toxic amyloid-beta 42 protein that forms plaques in the first place. The study shows the drug works during the neuron signaling cycle by binding to SV2A, keeping APP on the neuron surface and diverting it away from the pathway that creates the toxic peptide. Key insight: the intervention would likely need to happen very early, potentially 10–20 years before symptoms. Early data from patient records also suggests people taking levetiracetam had a small but meaningful delay in Alzheimer’s progression. Still early science, but this shifts the conversation from treating plaques to preventing them entirely.